Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis Relapse”

1,012 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,012 results

Not applicableStudy completedNCT02519413
What this trial is testing

Tecfidera Lymphocyte Chart Review

Who this might be right for
Multiple Sclerosis
Biogen 483
Large-scale testing (Phase 3)Study completedNCT00662649
What this trial is testing

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis 920
Large-scale testing (Phase 3)Not Yet RecruitingNCT07189325
What this trial is testing

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Anti-CD20 Therapy
University Hospital, Montpellier 250
Testing effectiveness (Phase 2)Study completedNCT00489489
What this trial is testing

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 118
Post-approval studies (Phase 4)Study completedNCT02048072
What this trial is testing

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Who this might be right for
Multiple SclerosisAutonomic Nervous System Dysfunction
Jochen Vehoff 33
Not applicableLooking for participantsNCT06586177
What this trial is testing

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf 100
Post-approval studies (Phase 4)UnknownNCT04048577
What this trial is testing

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Berkovich, Regina MD, PhD Inc. 10
Not applicableStudy completedNCT04115930
What this trial is testing

Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients

Who this might be right for
Relapsing Remitting Multiple SclerosisFatigueQuality of Life+1 more
University of Eastern Finland 61
Post-approval studies (Phase 4)Study completedNCT03385356
What this trial is testing

Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingVitamin D Deficiency
University Medical Centre Maribor 89
Testing effectiveness (Phase 2)Ended earlyNCT03183869
What this trial is testing

Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients

Who this might be right for
Autoimmune DiseasesRelapsing Multiple Sclerosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 14
Large-scale testing (Phase 3)Temporarily pausedNCT05441488
What this trial is testing

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Who this might be right for
Progressive Multiple Sclerosis
AB Science 800
Early research (Phase 1)Looking for participantsNCT07224373
What this trial is testing

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AstraZeneca 24
Not applicableUnknownNCT03787446
What this trial is testing

PET Study in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University of British Columbia 9
Testing effectiveness (Phase 2)Study completedNCT03381170
What this trial is testing

An Extension of the TG1101-RMS201 Trial

Who this might be right for
Relapsing Remitting Multiple Sclerosis
TG Therapeutics, Inc. 48
Not applicableStudy completedNCT02021162
What this trial is testing

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple SclerosisHealthy
University at Buffalo 50
Not applicableStudy completedNCT01142492
What this trial is testing

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 403
Not applicableStudy completedNCT04832399
What this trial is testing

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 60
Not applicableStudy completedNCT01281657
What this trial is testing

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

Who this might be right for
Multiple Sclerosis
Novartis 64
Not applicableStudy completedNCT00594087
What this trial is testing

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

Who this might be right for
Relapsing Remitting Multiple SclerosisSleep Initiation and Maintenance DisordersFatigue
University of Vermont 30
Testing effectiveness (Phase 2)Study completedNCT03889639
What this trial is testing

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Sanofi 130
Load More Results